A 43-year-old woman with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in acute phase received high-dose chemotherapy followed by transfusion of 12 randomly selected units of umbilical cord blood. HLA analysis showed cells of one donor from day +10 to day +43 post-transfusion. This unit was HLA class II identical with that of the patient. Keywords: placental blood; unmatched; multiple donors; CML There is considerable interest in umbilical cord blood (UCB) transplants (for reviews see Refs 1-4 7 who reported successful transplantation of the cord blood stem cells into a 26-year-old women. We report a patient who received 12 units of HLA-untyped UCB for CML in acute phase after high-dose chemotherapy.
treated with cytarabine to which she responded briefly. Based on a previously approved Institutional Review Board (IRB) transplantation protocol involving unrelated UCB and after informed consent, the patient received busulfan (12 mg/kg) and cyclophosphamide (120 mg/kg) followed by infusion of 3.18 × 10 9 mononuclear cells obtained from UCB from 12 unrelated donors.
On day +1 we began GVHD prophylaxis consisting of cyclosporine and solumedrol. Early signs of engraftment were observed on day +10 with islands of trilineage hematopoiesis noted in a bone marrow biopsy specimen. There were no clinical features of GVHD. Increased bilirubin developed between days +14 and +17 with a peak value at 7.6 mg/dl. The patient was discharged in a stable condition on day +21 with a WBC count of 2.6 × 10 9 /l. Fetal hemoglobinized RBC and RhD-positive RBC were detected in the blood between day +17 and day +21 (patient's blood type O RhD-negative). Southern blot analysis of DNA from blood cells on day +16 showed no bcr/abl rearrangement (previously detected). Growth factor therapy was stopped on day +31 when the WBC count was Ͼ10 × 10 9 /l. The WBC continued to rise and was 8.5 × 10 9 /l on day +53 with reappearance of Ph chromosome-positive cells. Hydroxyurea and interferon were begun on day +71 and she died on day +90 of leukemia.
Umbilical cord blood collecting and processing
Units of UCB were collected after fetal delivery during the third stage of labor, with the placenta in situ by cannulation of the umbilical vein using a 16-gauge needle attached to blood transfer pack. The collected cord bloods were processed using a modification of the technique described by Rubinstein et al. 8 Briefly, this involved the transfer of the blood to multiple sterile 50 ml conical tubes (Baxter Healthcare, Scientific Products Division, McGaw Park, IL, USA) using sterile technique in a laminar flow hood. After centrifugation (1500 g for 10 min at room temperature), the plasma supernatant was separated, and an aliquot of plasma was sent for disease marker testing. After addition of enough normal saline to bring the volume of the packed red blood cell/buffy coat preparation to 50 ml, the cells were again centrifuged. After centrifugation, the 'wash' supernatant was discarded and the interface 'buffy coat' preparation was transferred to a new appropriately marked tube. Immediately 8 ml (final concentration 1% hetastarch) of a sterile solution of 6% hetastarch (Hespan; Dupont Pharma, Wilmington, DE, USA) was added to the tube along with saline to a final mixture volume of 50 ml. The tube was gently mixed by inversion (10 ×) and centrifuged (1500 g for 10 min at room temperature). After centrifugation, a 15-cm 14-gauge cannula attached to a 60-ml syringe was carefully inserted through the buffy coat layer and the centrifuged red blood cells were aspirated away from the very bottom of the conical tube leaving the 'buffy coat'-rich, RBC-depleted portion of the collected blood. Cryopreservation of the processed cord blood used a 5% DMSO-6% Pentastarch-4% HSA mixture 9 with placement of each bag of processed cells into a Ϫ80°C mechanical freezer until use (approximately 3 weeks).
Hematopoietic progenitor cell assays
Granulocyte/macrophage (CFU-GM), multipotential (CFU-GEMM) and erythroid (BFU-E) progenitor cell enumeration assays were performed in duplicate with slight modification of previously described techniques. 10 
Detection of donor cell engraftment
HLA typing used sequence-specific oligonucleotide probes (SSOP). 11, 12 TNFb (tumor necrosis factor microsatellite b) microsatellite variants were determined as described. 13 HLA typing of the patient was achieved using the technique of sequence-specific primers (SSP) as previously described.
14 Detection and quantitation of RBC containing hemoglobin F (HbF) was performed using a modified Kleihauer-Betke technique. 15 Red blood cell RhD antigen phenotype determinations were assessed using a blended monoclonal/polyclonal anti-RhD antibody reagent (Ortho Diagnostic Systems, Raritan, NJ, USA) by tube agglutination method. 
Results
Characteristics of the 12 units of cord blood are presented in Table 1 . The patient's HLA type was identified as: A3, A11, B39, B70, DRB1 * 1101, DRB1 * 1301, DQB1 * 0301, DQB * 0603. HLA type and TNFb variant analyses of the various cord blood units and the patient post-transplant are listed in Tables 2 and 3 . Retrospective HLA typing showed limited sharing of loci amongst the 12 cord blood units. Compared to the patient's type, one of the transplanted cord blood unit (unit No. 69562) had three HLA class I mismatches and was HLA class II identical (Table 2 ). This particular cord blood unit's type was detectable from day +9 to +43 (Table 3 , Figure 1 ). Peak percentages (1.7%) of HbF-positive RBC were achieved on day +34 and declined thereafter. RhD-positive RBC was first detected on day +21 with mixed field aggregates appearing on day +32 and persisting until day +64.
Discussion
In the work presented here, an adult patient (43-years-old, 87 kg) with recurrent leukemia received 12 units of UCB from unrelated donors selected for ABO blood type similar to the patient. Our data indicate that one unit of UCB cells engrafted and persisted for about 43 days before relapse. This one unit had three HLA class I mismatches (two HLA-B, one HLA-A) and was HLA class II identical with the patient. Whether the 11 other units contributed to the outcome is unknown. In a second patient subsequently transplanted with multiple cord blood units, we have also identified the engraftment of HLA class I mismatched but HLA class II identical cells from one donor. This patient survived 68 days, dying of GVHD and infection. Further analysis of the relative contributions of various HLA regions to engraftment of HLA mismatched UCB cells appears warranted.
